Literature DB >> 21772053

Severe impairment of IFN-γ and IFN-α responses in cells of a patient with a novel STAT1 splicing mutation.

Donatella Vairo1, Laura Tassone, Giovanna Tabellini, Nicola Tamassia, Sara Gasperini, Flavia Bazzoni, Alessandro Plebani, Fulvio Porta, Luigi D Notarangelo, Silvia Parolini, Silvia Giliani, Raffaele Badolato.   

Abstract

Subjects affected by Signal Transducer and Activator of Transcription 1 (STAT1) deficiency have lethal bacterial and viral infections. Complete STAT1 deficiency is inherited as an autosomal recessive disease; partial STAT1 deficiency is inherited as an autosomal recessive or autosomal dominant trait. Here, we report a patient who developed disseminated mycobacteriosis early in life and had several viral infections, including herpetic skin infection and interstitial pneumonia by cytomegalovirus with severe respiratory distress. Molecular analysis of STAT1 showed a novel homozygous mutation affecting a splice site, leading to exon 3 skipping and to synthesis of a lower molecular weight STAT1 protein. This mutation leads to marked reduction of STAT1 phosphorylation; the electromobility shift assay showed a complete defect of DNA-binding activity, which accounts for the complete impairment of peripheral blood mononuclear cell functional response to both IFN-γ and IFN-α. Moreover, analysis of natural killer cells showed a defective STAT1 phosphorylation in response to IFN-α and impaired basal cytolytic activity, suggesting that the STAT1-dependent pathway might be important for natural killer cell function. These results suggested that exon 3 skipping of STAT1 leads to abnormal signaling in response to IFN-γ and IFN-α, which is associated with susceptibility to intracellular pathogens and viruses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21772053     DOI: 10.1182/blood-2011-01-330571

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  STAT1-deficient mice are resistant to cecal ligation and puncture-induced septic shock.

Authors:  Daniela Herzig; Geping Fang; Tracy E Toliver-Kinsky; Yin Guo; Julia Bohannon; Edward R Sherwood
Journal:  Shock       Date:  2012-10       Impact factor: 3.454

Review 2.  Natural killer cell deficiency.

Authors:  Jordan S Orange
Journal:  J Allergy Clin Immunol       Date:  2013-09       Impact factor: 10.793

Review 3.  The tiers and dimensions of evasion of the type I interferon response by human cytomegalovirus.

Authors:  Lisi Amsler; Marieke Verweij; Victor R DeFilippis
Journal:  J Mol Biol       Date:  2013-09-05       Impact factor: 5.469

4.  A novel STAT1 mutation associated with disseminated mycobacterial disease.

Authors:  Elizabeth P Sampaio; Hannelore I Bax; Amy P Hsu; Ervand Kristosturyan; Joseph Pechacek; Prabha Chandrasekaran; Michelle L Paulson; Dalton L Dias; Christine Spalding; Gulbu Uzel; Li Ding; Elizabeth McFarland; Steven M Holland
Journal:  J Clin Immunol       Date:  2012-02-29       Impact factor: 8.317

Review 5.  Incomplete penetrance in primary immunodeficiency: a skeleton in the closet.

Authors:  Conor Gruber; Dusan Bogunovic
Journal:  Hum Genet       Date:  2020-02-17       Impact factor: 4.132

6.  Overexpression of methyl-CpG binding protein 2 impairs T(H)1 responses.

Authors:  Tianshu Yang; Melissa B Ramocki; Jeffrey L Neul; Wen Lu; Luz Roberts; John Knight; Christopher S Ward; Huda Y Zoghbi; Farrah Kheradmand; David B Corry
Journal:  Sci Transl Med       Date:  2012-12-05       Impact factor: 17.956

7.  Heterozygosity for the Y701C STAT1 mutation in a multiplex kindred with multifocal osteomyelitis.

Authors:  Osamu Hirata; Satoshi Okada; Miyuki Tsumura; Reiko Kagawa; Mizuka Miki; Hiroshi Kawaguchi; Kazuhiro Nakamura; Stéphanie Boisson-Dupuis; Jean-Laurent Casanova; Yoshihiro Takihara; Masao Kobayashi
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

8.  Butyrate Reprograms Expression of Specific Interferon-Stimulated Genes.

Authors:  Mahesh Chemudupati; Adam D Kenney; Anna C Smith; Robert J Fillinger; Lizhi Zhang; Ashley Zani; Shan-Lu Liu; Matthew Z Anderson; Amit Sharma; Jacob S Yount
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

9.  Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.

Authors:  Alexander Vargas-Hernández; Emily M Mace; Ofer Zimmerman; Christa S Zerbe; Alexandra F Freeman; Sergio Rosenzweig; Jennifer W Leiding; Troy Torgerson; Matthew C Altman; Edith Schussler; Charlotte Cunningham-Rundles; Ivan K Chinn; Alexandre F Carisey; Imelda C Hanson; Nicholas L Rider; Steven M Holland; Jordan S Orange; Lisa R Forbes
Journal:  J Allergy Clin Immunol       Date:  2017-10-27       Impact factor: 10.793

Review 10.  A genetic perspective on granulomatous diseases with an emphasis on mycobacterial infections.

Authors:  Un-In Wu; Steven M Holland
Journal:  Semin Immunopathol       Date:  2016-01-05       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.